Publications by authors named "Blaise Robinson"
Article Synopsis
- Cancer patients often face harsh side effects from traditional treatments like chemotherapy and radiotherapy, leading to a push for more targeted therapies.
- Engineered immunotherapies show promise for better targeting and prevention of tumor growth, but issues like ineffective activation and unwanted side effects still need to be addressed.
- Prodrug therapies, which are activated selectively, could overcome these challenges by using advanced bioconjugation techniques for safer and more controlled delivery of immunotherapeutics.
The blood-brain barrier (BBB) is a highly selective network of various cell types that acts as a filter between the blood and the brain parenchyma. Because of this, the BBB remains a major obstacle for drug delivery to the central nervous system (CNS). In recent years, there has been a focus on developing various modifiable platforms, such as monoclonal antibodies (mAbs), nanobodies (Nbs), peptides, and nanoparticles, as both therapeutic agents and carriers for targeted drug delivery to treat brain cancers and diseases.
View Article and Find Full Text PDF